Optiscan Imaging has launched a 35-patient clinical trial in the US to test its InVue™ and InForm™ platforms in head and neck cancer surgery, aiming to bolster its FDA submissions later this year.
- New 35-patient US study on head and neck cancer initiated
- Focus on real-time surgical margin assessment with InVue™ and InForm™
- Collaboration with Mayo Clinic to generate data for FDA filings
- Study explores both in vivo and ex vivo imaging workflows
- Potential to broaden clinical applications and market reach
New Frontiers in Surgical Imaging for Head and Neck Cancer
Optiscan Imaging Ltd (ASX:OIL) has kicked off a pivotal US clinical study targeting the notoriously challenging head and neck cancer surgical space. The 35-patient trial, conducted in partnership with Mayo Clinic Rochester, will evaluate the performance of Optiscan’s InVue™ and InForm™ imaging platforms in assessing tumour margins during surgery. This initiative marks a strategic push to expand the company’s footprint beyond existing oncology applications, aiming to generate critical data for FDA regulatory submissions scheduled for later in 2026.
Head and neck cancer remains a significant global health burden, with nearly 890,000 new diagnoses and 450,000 deaths annually. Surgical removal of tumours in this region demands extreme precision to eradicate cancer while preserving vital functions like speech and swallowing. Recurrence rates hover around 50%, underscoring the urgent need for better intraoperative visualization tools. Optiscan’s technology seeks to fill this gap by providing surgeons with real-time, microscopic imaging to distinguish cancerous tissue from healthy structures.
Dual-Platform Approach for Comprehensive Imaging
The study uniquely combines in vivo and ex vivo imaging workflows. During surgery, the InVue™ device will be deployed to capture live microscopic images inside the surgical cavity immediately after tumour excision, utilising intravenous fluorescein sodium as a contrast agent. This real-time imaging aims to help surgeons identify residual cancerous tissue on the spot.
Following excision, tissue specimens will be analysed ex vivo using the InForm™ digital pathology platform, enhanced with topical Acridine Orange dye to facilitate high-resolution imaging. This complementary approach will assess how well InForm™ integrates into pathology workflows, generating a robust dataset that aligns intraoperative findings with post-surgical tissue analysis.
Regulatory and Commercial Implications
Data from this study will be a cornerstone of Optiscan’s FDA submissions for both devices, providing evidence of performance across multiple tissue types and clinical settings. The comprehensive in vivo and ex vivo imaging data package is designed to demonstrate the platforms’ clinical utility and workflow integration, potentially smoothing regulatory pathways.
Beyond regulatory milestones, head and neck cancer surgery represents a substantial commercial opportunity. Success in this study could accelerate adoption of Optiscan’s technologies by healthcare providers seeking enhanced imaging capabilities during surgery and pathology. Moreover, demonstrating the complementary value of InVue™ and InForm™ within a single clinical workflow could open doors to broader applications, including other cancer types and surgical procedures, as well as digital pathology and AI-enabled solutions.
Leadership Perspective on Clinical Expansion
Optiscan CEO Dr Camile Farah emphasised the strategic importance of this study, highlighting the unmet clinical need in head and neck cancer surgery. “Despite advances in treatment, recurrence remains a major challenge,” she said. “We’re keen to understand how real-time imaging can support surgical decision-making and improve patient outcomes.”
Dr Farah also pointed to the versatility of Optiscan’s platforms as a key differentiator. “If the study confirms the role of real-time imaging in this complex surgical setting, it will reinforce the broader impact InVue™ and InForm™ can have across multiple cancer types and clinical environments.”
This trial builds on Optiscan’s ongoing clinical collaborations and regulatory efforts, following recent progress in breast cancer imaging studies and FDA approvals in related markets. It will be critical to monitor recruitment progress and emerging data as the company advances its US regulatory agenda.
Bottom Line?
Optiscan’s head and neck cancer study could be a crucial stepping stone for FDA approval and market expansion, but the small patient cohort means outcomes remain uncertain.
Questions in the middle?
- How will data from this study influence FDA approval timelines for InVue™ and InForm™?
- Can Optiscan’s imaging platforms significantly reduce recurrence rates in head and neck cancer surgery?
- What commercial partnerships or market expansions might follow successful trial results?